Leuprolide
Leuprolide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Early Breast Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
7 项
已进入 III/IV 期
9 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Novartis Pharmaceuticals
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- SWOG Cancer Research Network
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- University of Michigan Rogel Cancer Center
- M.D. Anderson Cancer Center
- City of Hope Medical Center
- Proton Collaborative Group
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、Chile、Colombia、Mexico、瑞士、意大利、英国、比利时
正在招募患者的 Leuprolide 研究
Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect
不适用招募中中国NCT05206682Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
III 期招募中美国ChileColombiaMexicoNCT03678025The COSMYC Trial (COmbined Suppression of MYC)
II 期招募中美国NCT06922318Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
II 期招募中美国NCT07158021Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
II 期招募中美国NCT05873192Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
II 期招募中美国NCT04734730Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
II 期招募中美国NCT06059118Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
III 期招募中美国NCT01492972Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway
不适用招募中意大利NCT07187947Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
不适用招募中美国NCT07142967Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
III 期招募中英国NCT07751133ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
II 期招募中美国NCT06397703Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients
II 期招募中中国NCT06832774Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
II 期招募中美国NCT07142551Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
I 期 / II 期招募中美国NCT07182279Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer
不适用招募中中国NCT05945407Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
III 期招募中中国NCT05891093Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
III 期招募中美国NCT04423211Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
III 期招募中比利时NCT05352178Kisspeptin Administration Subcutaneously to Patients With IHH
II 期招募中美国NCT05896293Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
II 期招募中中国NCT06348264Autonomic and Renal Contributions to Hypertension With ADT
IV 期招募中美国NCT07848828Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
II 期招募中美国NCT06330805Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
II 期招募中中国NCT05406999
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。